To The Moon

Data from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research Annual Meeting. "We're excited that the EVANGELINE data from the 40 mg cohort of patients was accepted for presentation at the 2024 American Association for Cancer Research Annual Meeting," said Dr. Steven Quay, Atossa's President and Chief Executive Officer. "While neoadjuvant therapy is effective and widely used across many cancer types, the current treatment options for premenopausal women diagnosed with ER+ breast cancer are sub-optimal. An effective and tolerable neoadjuvant therapy would transform the treatment approach in this setting, making surgery more effective and reducing the likelihood that the cancer will recur. There is growing excitement and understanding across the breast cancer community that -endoxifen, if shown to be safe and effective, would be a game changer for premenopausal women."

Annual responsibility report covers labor, energy, Covid-19 Apple stopped providing specific address